Steps taken for advancing personalized medicine

1. At a Glance

• Personalized (precision) medicine = tailoring prevention, diagnosis & therapy to an individual's genomic, phenotypic, lifestyle and clinical profile.
• India's push rests on four pillars: GenomeIndia (WGS reference), Phenome India biobank, BioE3 Policy (precision biotherapeutics), and UMMID/NIDAN Kendras for inherited disorders [S1][S2][S3].
• UPSC relevance: cross-cuts GS-III S&T, biotechnology policy, public health, and ethical/data-governance debates.

2. Why in the News

• May 2025 MoHFW/DBT statement consolidates steps for advancing personalized medicine: GenomeIndia crosses 10,000 WGS milestone; Phenome India National Biobank launched at CSIR-IGIB, New Delhi; BioE3 funding calls opened for mRNA, mAbs, cell/gene therapy; NIDAN Kendras expanded; InTGS consortium catalogues TB drug-resistance mutations [S1].

3. Background & Evolution

• 2020 (Jan): GenomeIndia Project launched by DBT; consortium of 20 institutions coordinated by Centre for Brain Research (CBR), IISc Bengaluru [S2][S3].
• 2019–20: UMMID Initiative & first NIDAN Kendras rolled out by DBT for inherited disorders [S5].
• Aug 2024: Union Cabinet approved BioE3 Policy (Biotechnology for Economy, Environment & Employment) [S4].
• Jan 2025: Genomic data of 10,000 Indians made available for research at Indian Biological Data Centre (IBDC), RCB Faridabad [S2][S3].
• 2025: Phenome India National Biobank operationalised at CSIR-IGIB for 10,000-cohort longitudinal study [S1].

4. Core Static Facts

• Nodal ministry: Ministry of Science & Technology — Department of Biotechnology (DBT); CSIR labs under DSIR; clinical arm via MoHFW [S1][S3].
• GenomeIndia: 10,000+ WGS across diverse Indian population groups; data hosted at IBDC, RCB Faridabad; future target 10 million genomes [S2][S3].
• Phenome India Biobank: at CSIR-Institute of Genomics & Integrative Biology (IGIB), New Delhi; captures genomic + lifestyle + clinical data of 10,000 individuals [S1].
• BioE3 Policy (2024): six thematic sectors — bio-based chemicals/enzymes, smart proteins, precision biotherapeutics, climate-resilient agri, carbon capture, marine & space bio; enablers = Bio-AI Hubs, Biofoundries, Biomanufacturing Hubs [S4][S6].
• UMMID = Unique Methods of Management & treatment of Inherited Disorders; NIDAN = National Inherited Diseases AdministratioN; functions: prenatal testing, newborn screening, genetic counselling [S5].
• InTGS = Indian Tuberculosis Genomic Surveillance Consortium — catalogues TB drug-resistance mutations using genomics + AI [S1].

5. Multi-Dimensional Analysis

Scientific / Technological - WGS of 10,000 Indians builds first reference dataset capturing India's endogamous-population diversity, enabling identification of population-specific variants [S2][S3]. - BioE3 funds indigenous mRNA therapeutics, monoclonal antibodies, cell & gene therapies via DBT-BIRAC joint calls [S6].

Economic - BioE3 targets the bio-economy as a future growth engine alongside space economy; promotes high-performance biomanufacturing & jobs [S4]. - Aims to reduce import dependence for advanced biologics (mAbs, gene therapies cost ₹crores per dose abroad).

Social / Public Health - NIDAN Kendras address sickle cell, thalassaemia, Duchenne, inborn errors of metabolism prevalent in tribal & consanguineous populations [S5]. - InTGS strengthens India's response to MDR/XDR-TB, a major social health burden [S1].

Ethical / Governance - Genomic data raises issues of privacy, informed consent, insurance discrimination — governed under DPDP Act 2023 and DBT bioethics guidelines. - Need for transparent data-sharing frameworks at IBDC.

Administrative - Multi-ministry coordination: DBT (genomics), CSIR (biobank), MoHFW (clinical translation), BIRAC (industry funding).

6. Recent Developments (12-18 months)

• Aug 2024: Cabinet clears BioE3 Policy [S4].
• 2024-25: DBT-BIRAC joint calls under BioE3 on mRNA therapeutics and cell/gene therapy [S6].
• Jan 2025: GenomeIndia data of 10,000 genomes opened via IBDC portal [S2].
• 2025: Phenome India National Biobank launched at CSIR-IGIB [S1].
• 2025: InTGS publishes catalogue of TB drug-resistance mutations [S1].

7. Prelims Hooks

• GenomeIndia is funded by DBT, coordinated by CBR-IISc Bengaluru [S3].
• GenomeIndia launched in January 2020 [S3].
• Genomic data hosted at Indian Biological Data Centre (IBDC), RCB Faridabad [S2].
• 20 institutions form the GenomeIndia consortium [S3].
• Phenome India National Biobank is at CSIR-IGIB, New Delhi [S1].
• BioE3 Policy approved by Cabinet in August 2024 [S4].
• BioE3 expands to Biotechnology for Economy, Environment and Employment [S4].
• BioE3 has six thematic sectors; precision biotherapeutics is one [S6].
• BioE3 enablers: Bio-AI Hubs, Biofoundries, Biomanufacturing Hubs [S6].
• UMMID = Unique Methods of Management and treatment of Inherited Disorders [S5].
• NIDAN Kendra delivers prenatal testing, newborn screening, genetic counselling [S5].
• InTGS uses genomics + AI for TB drug-resistance surveillance [S1].
• Future target announced: sequencing 10 million genomes [S2].

8. Mains Relevance

• GS-III: Science & Technology — Developments and applications in everyday life; Biotechnology; Indigenisation of technology.
• GS-II: Health — Issues relating to development of social sectors.
• Probable stems: 1. "Personalized medicine promises equitable health gains only if backed by indigenous biomanufacturing. Discuss with reference to BioE3 Policy and GenomeIndia." 2. "Examine the ethical and data-governance challenges of large population-scale genomic databases in India." 3. "How can genomic surveillance transform India's response to drug-resistant tuberculosis?"

9. Related Topics to Study Next

• BioE3 Policy 2024 — parent policy for biomanufacturing.
• National Biopharma Mission / BIRAC — funding arm enabling precision biotherapeutics.
• Sickle Cell Anaemia Elimination Mission (2023) — clinical use case for genomic screening.
• Digital Personal Data Protection Act 2023 — governs genomic data.
• National TB Elimination Programme — InTGS feeds into this.
• CRISPR/Gene Editing Regulation (DBT 2022 guidelines) — therapy approvals.
• AI in Healthcare (AIRAWAT, IndiaAI Mission) — for phenome analytics.
• Ayushman Bharat Digital Mission — clinical data linkage.

10. Common Errors / Trap Areas

• GenomeIndia is coordinated by CBR-IISc, not by ICMR or AIIMS [S3].
• Genomic data centre is IBDC at RCB Faridabad, not at NCBS or NIBMG [S2].
• BioE3 is a DBT policy, not a MoHFW or MeitY policy [S4].
• UMMID/NIDAN target inherited disorders, distinct from the Sickle Cell Mission (though overlapping).
• Phenome India biobank is at CSIR-IGIB, distinct from the older CSIR Phenome India "Cardio-metabolic" cohort branding — both are IGIB-led [S1].

11. Sources

• [S1] Steps taken for advancing personalized medicine — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2224521 — (tier 1)
• [S2] India Takes a Giant Leap in Genomics: Launch of Indian Genomic Data Set & IBDC Portals — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2091577 — (tier 1)
• [S3] GenomeIndia — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2125504 — (tier 1)
• [S4] Cabinet approves BioE3 Policy — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2048569 — (tier 1)
• [S5] Inauguration Nidan Kendras and UMMID Launch — https://dbtindia.gov.in/dbt-press/inauguration-nidan-kendras-and-ummid-launch-dbt-website — (tier 1)
• [S6] Aims and Objectives of BioE3 Policy — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2078063 — (tier 1)